What is recorded here?
A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.
Read the original work
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography
- Druker and colleagues: original phase 1 trial abstract
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Brian J. Druker; Moshe Talpaz; Debra J. Resta; Bin Peng; Elisabeth Buchdunger; John M. Ford; Nicholas B. Lydon; Hagop Kantarjian; Renaud Capdeville; Sayuri Ohno-Jones; Charles L. Sawyers
Source-paper byline retained. This is not a complete roster of a lifetime project or verified unique person identities.
Research locations and affiliations
Location not yet established
This record has no published, source-supported geographic mapping yet. Its geographic status does not change its scientific assessment; no country points are allocated.
English catalogue narrative
Imatinib: testing a cancer drug against a defined molecular target
A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.
Scientific scope
The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Brian J. Druker; Moshe Talpaz; Debra J. Resta; Bin Peng; Elisabeth Buchdunger; John M. Ford; Nicholas B. Lydon; Hagop Kantarjian; Renaud Capdeville; Sayuri Ohno-Jones; Charles L. Sawyers
Source-paper byline retained. This is not a complete roster of a lifetime project or verified unique person identities.